Prescription Required
Brilinta 90mg Tablet 14s is an antiplatelet medication prescribed to reduce the risk of blood clots, heart attack, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. Manufactured by AstraZeneca, this drug plays a vital role in improving cardiovascular outcomes for high-risk patients. By preventing platelets from clumping together, BRILINTA ensures smooth blood flow and minimizes the risk of life-threatening cardiovascular events.
Limited data; consult healthcare provider for personalized advice.
Limited data; consult healthcare provider for personalized advice.
Limited data; consult healthcare provider for personalized advice.
Limited data; consult healthcare provider for personalized advice.
Regular liver function assessment is advisable during usage.
No effect in driving ability.
A reversible P2Y12 receptor antagonist that prevents platelet activation and aggregation. BRILINTA inhibits the P2Y12 receptor on platelets, blocking the action of adenosine diphosphate (ADP). This reduces the platelets' ability to clump together, thereby lowering the risk of clot formation.
ACS refers to conditions caused by reduced blood flow to the heart, leading to symptoms such as chest pain, shortness of breath, and fatigue. It includes:
Brilinta 90mg Tablet is an effective antiplatelet medication for reducing the risk of blood clots, heart attack, and stroke in high-risk patients. Its unique mechanism of action ensures reversible platelet inhibition, making it a versatile choice for managing acute coronary syndrome and post-myocardial infarction patients.
Content Updated on
Monday, 21 April, 2025Prescription Required
Simplify your healthcare journey with Indian Government's ABHA card. Get your card today!
Create ABHA